Clinical efficacy of casirivimab and imdevimab in preventing COVID-19 in the Omicron BA.5 subvariant epidemic: a retrospective study

Abstract Background The neutralizing monoclonal antibody combination of casirivimab and imdevimab (CAS + IMD) is the only therapy approved for preventing coronavirus disease 2019 (COVID-19) following exposure to severe acute respiratory syndrome coronavirus 2. However, the efficacy of CAS + IMD agai...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Mariko Ohtani, Takuya Yokoo, Taito Miyazaki, Hiroshi Yasuda, Eriko Nishikawa, Manabu Tomida, Mayumi Tsukada, Emi Sato, Shinobu Hirayama, Hinako Murakami, Sadako Yoshizawa, Takahiro Matsumoto, Kazuhiro Tateda
Format:	Artigo
Jezik:	Inglês
Izdano:	BMC 2025-10-01
Serija:	Journal of Pharmaceutical Health Care and Sciences
Teme:	COVID-19 Casirivimab Imdevimab Post-exposure prophylaxis Omicron
Online dostop:	https://doi.org/10.1186/s40780-025-00501-x
Oznake:	Označite Brez oznak, prvi označite!